PLA2R1 and kidney disorder: Kidney Disease Improving Global Outcomes (KDIGO) 2021 guidelines recommend anti-PLA2R antibody as a laboratory index for diagnosis, treatment effectiveness analysis, and prognostic evaluation (Du et al., 2014; Hofstra et al., 2012).